Treatment response and white matter hyperintensities in 328 patients with new daily persistent headache: A retrospective real-world study

Background and aims New daily persistent headache (NDPH) is a primary headache disorder characterized by the abrupt onset of continuing and unremitting headache within 24 h of onset. Diagnosis is clinical, requiring exclusion of secondary causes, with limited imaging and treatment data. We assessed the prevalence of nonspecific white matter hyperintensities (WMH) and treatment response in a large retrospective cohort with primary NDPH. Methods A retrospective chart review was conducted on 328 patients diagnosed with NDPH by a headache subspecialist over an 8.5-year period. Patients were classified into the migraine phenotype (MP; n = 260) or tension-type phenotype (TTP; n = 50) based on associated features. The presence of WMH reported on MRI scans and acute and preventive treatment responses were evaluated. Results WMH were reported in 20.9% of MP patients (33/158) and 18.0% of TTP patients (9/50), p = .658. Acute treatments for the MP and TTP were minimally, if at all, effective. Preventive treatments generally had limited effectiveness. For the MP, the percentages of patients achieving a 30% or greater reduction in headache days per month were the following: desvenlafaxine, 54.5%; venlafaxine, 41.2%; and onabotulinumtoxinA, 27.9%. Venlafaxine was the most effective for the TTP with 25% having a 30% or greater reduction in headache days. Greater occipital and pericranial nerve blocks were mildly effective while surgical procedures were largely ineffective. Up to five day inpatient intravenous regimens with dihydroergotamine produced temporary benefit in 41.7%. Conclusions WMH are present in a minority of NDPH patients. Acute treatment is largely not effective. Preventive treatments were more effective in those with MP than TTP with many failures. Future prospective studies with new treatments are needed to identify effective interventions for this often disabling and refractory disorder.

Authors

Institutions

Publication Details

Journal
Cephalalgia Reports
Published
2025-10-01
DOI
https://doi.org/10.1177/25158163251386409
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment response and white matter hyperintensities in 328 patients with new daily persistent headache: A retrospective real-world study

Dana P. Turner, Randolph W. Evans
Cephalalgia Reports
Migraine and Headache Studies
article

Treatment response and white matter hyperintensities in 328 patients with new daily persistent headache: A retrospective real-world study

Dana P. Turner, Randolph W. Evans
article en

Abstract

Background and aims New daily persistent headache (NDPH) is a primary headache disorder characterized by the abrupt onset of continuing and unremitting headache within 24 h of onset. Diagnosis is clinical, requiring exclusion of secondary causes, with limited imaging and treatment data. We assessed the prevalence of nonspecific white matter hyperintensities (WMH) and treatment response in a large retrospective cohort with primary NDPH. Methods A retrospective chart review was conducted on 328 patients diagnosed with NDPH by a headache subspecialist over an 8.5-year period. Patients were classified into the migraine phenotype (MP; n = 260) or tension-type phenotype (TTP; n = 50) based on associated features. The presence of WMH reported on MRI scans and acute and preventive treatment responses were evaluated. Results WMH were reported in 20.9% of MP patients (33/158) and 18.0% of TTP patients (9/50), p = .658. Acute treatments for the MP and TTP were minimally, if at all, effective. Preventive treatments generally had limited effectiveness. For the MP, the percentages of patients achieving a 30% or greater reduction in headache days per month were the following: desvenlafaxine, 54.5%; venlafaxine, 41.2%; and onabotulinumtoxinA, 27.9%. Venlafaxine was the most effective for the TTP with 25% having a 30% or greater reduction in headache days. Greater occipital and pericranial nerve blocks were mildly effective while surgical procedures were largely ineffective. Up to five day inpatient intravenous regimens with dihydroergotamine produced temporary benefit in 41.7%. Conclusions WMH are present in a minority of NDPH patients. Acute treatment is largely not effective. Preventive treatments were more effective in those with MP than TTP with many failures. Future prospective studies with new treatments are needed to identify effective interventions for this often disabling and refractory disorder.

Cephalalgia ReportsVol. 8
Harvard University (US), Baylor College of Medicine (US), Massachusetts General Hospital (US)
Openalex Percentile: Top 66%
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.